Omeros Corporation's Narsoplimab Presentations at Tandem Meetings

Omeros Corporation's Insightful Presentations at Upcoming Meetings

Omeros Corporation (NASDAQ: OMER) is poised to showcase significant advancements in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) through its innovative drug, Narsoplimab. At the forthcoming 2025 Tandem Meetings, scheduled for mid-February in Honolulu, Omeros will feature two key presentations that highlight the real-world results of this treatment under an expanded access program.

Presenting Real-World Outcomes from Narsoplimab Treatment

Both presentations serve as a vital platform to share insights into how Narsoplimab, a fully human monoclonal antibody, is making a substantial difference in the lives of patients suffering from TA-TMA, which is a severe and often fatal condition resulting from stem cell transplants. The first presentation will offer crucial data on the overall survival rates of 128 transplant patients treated under the expanded access program, illuminating the promising effects of this treatment.

Podium Presentation by Michelle Schoettler, M.D.

During an oral abstract session on February 13, Dr. Michelle Schoettler, a distinguished Assistant Professor at Emory University School of Medicine, will present the findings of the survival rates post-treatment. This analysis is significant as it not only highlights the potential benefits of Narsoplimab but also contributes to the broader understanding of TA-TMA outcomes compared to standard care options.

Poster Presentation by Piyatida Chumnumsiriwath, M.D.

The second presentation will be led by Dr. Piyatida Chumnumsiriwath from the University of California, Irvine, where they will discuss the experiences of adult patients receiving Narsoplimab after ineffective treatment with eculizumab. This poster session will delve into the specific challenges and outcomes of this group of patients, providing further context to the necessity and effectiveness of Narsoplimab.

Key Presentation Details

The details of the presentations are already listed on the Tandem Meetings website, making them accessible for further information and context. For those interested in attending, the presentations are set to cover:

• Narsoplimab Treatment for Hematopoietic Cell Transplant Associated Thrombotic Microangiopathy - Date: February 13, 2025
  Time: 3:15-3:30 p.m. HST
  Location: Ballroom A (HCC)
• Narsoplimab for Refractory Transplantation-Associated Thrombotic Microangiopathy - Date: February 13, 2025
  Time: 6:45-7:45 p.m. HST
  Location: Exhibit Hall 3 (HCC)

About Narsoplimab and Its Importance

Narsoplimab, also known as OMS721, represents a groundbreaking therapeutic option for patients suffering from TA-TMA. This investigational drug targets mannan-binding lectin-associated serine protease-2 (MASP-2), enhancing the body's natural immune response while sparing the classical complement pathway crucial for fighting infections. Currently, the FDA has granted breakthrough therapy and orphan drug designations for Narsoplimab, underscoring its potential significance in treating TA-TMA.

Understanding Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

This complex disorder illustrates a severe side effect of stem cell transplants, where damage to endothelial cells leads to various life-threatening complications. Understanding the pathology of TA-TMA is key for developing effective therapeutics like Narsoplimab. The condition's high mortality rate points to a need for innovative treatment options, as existing therapies have not been effective for many patients.

Omeros Corporation: A Leader in Innovative Biopharmaceuticals

Omeros significantly influences the biopharmaceutical landscape by focusing on innovative solutions for unmet medical needs, especially in immunologic and hematologic disorders. With ongoing developments in their pipeline, including clinical trials for their MASP-2 inhibitor, Omeros is committed to improving health outcomes for patients across various indications encompassing cancers and other severe conditions.

Frequently Asked Questions

What is Narsoplimab?

Narsoplimab is an investigational drug targeting MASP-2, designed to treat TA-TMA by modulating the immune response.

Where will the presentations take place?

The presentations will occur at the 2025 Tandem Meetings in Honolulu from February 12-15, 2025.

Who will be presenting the findings?

Dr. Michelle Schoettler and Dr. Piyatida Chumnumsiriwath will present the findings on Narsoplimab's effectiveness in treating TA-TMA.

Is there any approved therapy for TA-TMA?

No, currently there is no approved therapy or standard care specifically for TA-TMA, making research like this crucial.

What recognition has Narsoplimab received from regulatory bodies?

The FDA has granted both breakthrough therapy and orphan drug designations to Narsoplimab for treating TA-TMA.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.